新型β-内酰胺类/β-内酰胺酶抑制剂复合制剂头孢吡肟-他尼硼巴坦钠的研究进展  

Research Progress in Novelβ-Lactam/β-Lactamase Inhibitor Compound Preparation Cefepime-Taniborbactam Sodium

作　　者：侯举 夏延哲[2] 李佳[2] HOU Ju;XIAYan-zhe;LI Jia(Pharmacy Department,the First Hospital of Changsha,Changsha 410005,China;Department of Pharmacy,the First Affiliated Hospital of Sun Yat-sen University,Guangzhou 510080,China)

机构地区：[1]长沙市第一医院药剂科,长沙410005 [2]中山大学附属第一医院药学部,广州510080

出　　处：《抗感染药学》2024年第10期983-987,共5页Anti-infection Pharmacy

基　　金：长沙市卫生健康委科研计划项目(编号:KJ-B2023041);广东省医院药学研究基金-抗菌药物专项研究基金(编号:2023KJ20)。

摘　　要：细菌耐药是一个全球性的公共卫生问题,尤其是碳青霉烯类耐药的革兰阴性菌(carbapenem-resistant Gram-negative bacteria,CR-GNB)的危害尤为严重。临床对CR-GNB感染的防治手段非常有限,故迫切需要新型抗菌药物。头孢吡肟-他尼硼巴坦钠是由第4代头孢菌素头孢吡肟和新型广谱β-内酰胺酶抑制剂他尼硼巴坦钠组成的复方制剂,其对A、B、C和D 4类β-内酰胺酶都具有直接的抑制活性,因而可能对CR-GNB等耐药菌具有较好的抗菌作用。该文从头孢吡肟和他尼硼巴坦钠的作用机理、药学特性、抗菌活性、临床研究、抑酶/抑菌谱等方面进行了综述,从而为头孢吡肟-他尼硼巴坦钠的临床合理应用提供参考。Bacterial resistance is a global public health problem,especially carbapenem-resistant Gram-negative bacteria(CR-GNB)have more serious harm.Clinically,there are very limited methods for prevention and treatment of CR-GNB infection,so novel antibacterial drugs are urgently needed.Cefepime-taniborbactam sodium is a compound preparation composed of the fourth-generation cephalosporin cefepime and the novel broad-spectrumβ-lactamase inhibitor taniborbactam sodium,and has direct inhibitory activity against four types ofβ-lactamases(types A,B,C and D),so it may have good antibacterial effects on CR-GNB and other drug-resistance bacteria.In this article,the mechanism of action,pharmaceutical properties,antibacterial activity,clinical study,enzyme inhibition/antibacterial spectrum of cefepime and taniborbactam sodium are reviewed,so as to provide reference for the rational clinical use of cefepime-taniborbactam sodium.

关 键 词：头孢吡肟-他尼硼巴坦钠 Β-内酰胺类药物 Β-内酰胺酶抑制剂 碳青霉烯类耐药的革兰阴性菌 

分 类 号：R978.11[医药卫生—药品] R961[医药卫生—药学]